2026-10-14T06:13:26Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33970636 2026-09-23T04:49:09Z category_19 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Efficacy and mechanisms of andrographolide derivative in acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis, network pharmacology, molecular docking, and in vitro validation study.docx Jiaxiang Li (5012060) Xiaowen Wu (1920451) Yuning Shen (2741161) Jiayang Yao (25094137) Zhiyue Yu (23029245) Ming Gao (115719) Weihao Gao (12986006) Limei Geng (23029248) Pharmacology acute exacerbation of COPD andrographolide derivatives inflammation meta-analysis molecular docking network pharmacology Background<p>Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) contributes substantially to morbidity and mortality. Andrographolide derivative injections (e.g., Xiyanping, Yanhuning, Chuanhuning, Lianbizhi) are widely used adjunctive treatments in China. Their clinical efficacy remains unclear, and we explored the potential mechanisms of the parent compound andrographolide in this study.</p>Methods<p>A systematic review and meta-analysis of 32 randomized controlled trials (n = 2,668) comparing andrographolide derivatives plus conventional therapy versus conventional therapy alone in patients with AECOPD was conducted. Pulmonary function (FEV₁%, FEV₁, FVC), arterial oxygen tension (PaO₂), inflammatory markers (CRP, WBC, NEUT%, PCT), and overall clinical response were evaluated. Network pharmacology, molecular docking, and in vitro experiments using LPS-stimulated BEAS-2B cells were performed to explore underlying mechanisms.</p>Results<p>Adjunctive andrographolide derivatives significantly improved overall clinical response rate [RR = 1.21, 95% CI 1.17–1.26, P < 0.00001], FEV₁% [MD = 6.48, 95% CI 3.52–9.45], FEV₁ [MD = 0.30 L, 95% CI 0.20–0.40], FVC [MD = 0.28 L, 95% CI 0.10–0.46], and PaO₂ [MD = 6.56 mmHg, 95% CI 4.68–8.45]. Inflammatory markers were also reduced: CRP [MD = −4.72 mg/L, 95% CI -6.83 to –2.61], WBC [MD = −1.30 ×10⁹/L, 95% CI −1.79 to −0.80], NEUT% [MD = −4.36 percentage points, 95% CI -6.18 to −2.54], PCT [MD = −0.17 ng/mL, 95% CI -0.23 to −0.10] (all P < 0.0001). Network pharmacology identified 39 overlapping targets, highlighting TNF, IL-1β, NLRP3, and CASP1 as core targets. Molecular docking suggested energetically favorable predicted interactions of andrographolide with NLRP3, caspase-1, IL-1β, and IL-18. In vitro, andrographolide enhanced BEAS-2B cell viability, reduced LDH release, and suppressed NLRP3, caspase-1, IL-1β, and TNF-α expression.</p>Conclusion<p>Andrographolide derivative injections as adjunctive therapy may improve clinical response, pulmonary function, oxygenation, and inflammatory status in patients with AECOPD. Mechanistic experiments using the parent compound andrographolide suggest that these therapeutic effects are potentially mediated by the NLRP3/caspase-1/IL-1β inflammatory axis. Nevertheless, these findings should be interpreted cautiously given the exclusively Chinese single-center RCTs, substantial heterogeneity in some outcomes, and lack of direct mechanistic data on individual derivatives.</p> 2026-09-23T04:49:09Z Dataset Dataset 10.3389/fphar.2026.1915339.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Efficacy_and_mechanisms_of_andrographolide_derivative_in_acute_exacerbations_of_chronic_obstructive_pulmonary_disease_a_meta-analysis_network_pharmacology_molecular_docking_and_in_vitro_validation_study_docx/33970636 CC BY 4.0